Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective Transport von Al-Bustami, H., Khaldi, S., Shoseyov, O., Yochelis, S., Killi, K., Berg, I., Gross, E., Paltiel, Y., Yerushalmi, R.

Volltext

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial von Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

Volltext

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the... von Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

Volltext

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning : the role of dose intensity von SHIMONI, A, HARDAN, I, SHEM-TOV, N, YESHURUN, M, YERUSHALMI, R, AVIGDOR, A, BEN-BASSAT, I, NAGLER, A

Volltext

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial von Goetz, M.P., Bagegni, N.A., Batist, G., Brufsky, A., Cristofanilli, M.A., Damodaran, S., Daniel, B.R., Fleming, G.F., Gradishar, W.J., Graff, S.L., Grosse Perdekamp, M.T., Hamilton, E., Lavasani, S., Moreno-Aspitia, A., O’Connor, T., Pluard, T.J., Rugo, H.S., Sammons, S.L., Schwartzberg, L.S., Stover, D.G., Vidal, G.A., Wang, G., Warner, E., Yerushalmi, R., Plourde, P.V., Portman, D.J., Gal-Yam, E.N.

Volltext

Breast carcinoma—rare types: review of the literature von Yerushalmi, R., Hayes, M. M., Gelmon, K. A.

Volltext

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome von Yerushalmi, R., Tyldesley, S., Kennecke, H., Speers, C., Woods, R., Knight, B., Gelmon, K.A.

Volltext

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced von Shimoni, A, Shem-Tov, N, Chetrit, A, Volchek, Y, Tallis, E, Avigdor, A, Sadetzki, S, Yerushalmi, R, Nagler, A

Volltext

Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies von Yerushalmi, R, Shem-Tov, N, Danylesko, I, Avigdor, A, Nagler, A, Shimoni, A

Volltext

Malignancy associated SIADH: Characterization and clinical implications von Goldvaser, H, Rozen-Zvi, B, Yerushalmi, R, Gafter-Gvili, A, Lahav, M, Shepshelovich, D

Volltext

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 von Magen, H, Fried, S, Itzhaki, O, Shem-Tov, N, Danylesko, I, Yerushalmi, R, Marcus, R, Shouval, R, Nevo, L, Shapira-Frommer, R, Nagler, A, Shimoni, A, Shkury, E, Avigdor, A

Volltext

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity von Shimoni, A, Shem-Tov, N, Volchek, Y, Danylesko, I, Yerushalmi, R, Nagler, A

Volltext

POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA von Magen, H., Fried, S., Itzhaki, O., Shem‐Tov, N., Danylesko, I., Yerushalmi, R., Marcus, R., Shouval, R., Nevo, L., Shapira‐Frommer, R., Nagler, A., Shimoni, A., Shkury, E., Avigdor, A.

Volltext

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials von Yerushalmi, R., Dong, B., Chapman, J.W., Goss, P.E., Pollak, M.N., Burnell, M.J., Levine, M.N., Bramwell, V.H.C., Pritchard, K.I., Whelan, T.J., Ingle, J.N., Shepherd, L.E., Parulekar, W.R., Han, L., Ding, K., Gelmon, K.A.

Volltext

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations von Lewin, R., Sulkes, A., Shochat, T., Tsoref, D., Rizel, S., Liebermann, N., Hendler, D., Neiman, V., Ben-Aharon, I., Friedman, E., Paluch-Shimon, S., Margel, D., Kedar, I., Yerushalmi, R.

Volltext

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up von Shimoni, A, Hardan, I, Shem-Tov, N, Yerushalmi, R, Nagler, A

Volltext

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? von Yerushalmi, R., Tyldesley, S., Woods, R., Kennecke, H.F., Speers, C., Gelmon, K.A.

Volltext

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data von Rotem, O., Peretz, I., Leviov, M., Kuchuk, I., Itay, A., Tokar, M., Paluch-Shimon, S., Maimon, O., Yerushalmi, R., Drumea, K., Evron, E., Sonnenblick, A., Gal-Yam, E., Goldvaser, H., Yosef, S., Merose, R., Bareket-Samish, A., Soussan-Gutman, L., Stemmer, S.M.

Volltext

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation von Tsirigotis, P, Danylesko, I, Gkirkas, K, Shem-Tov, N, Yerushalmi, R, Stamouli, M, Avigdor, A, Spyridonidis, A, Gauthier, J, Goldstein, G, Apostolidis, J, Mohty, M, Shimoni, A, Nagler, A

Volltext

PAGET'S DISEASE AND MALE BREAST CANCER von Yerushalmi, R, Sulkes, A

Volltext